Ligand Pharmaceuticals (LGND) Net Cash Flow Growth (1y) (2011 - 2026)
Ligand Pharmaceuticals (LGND) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn | 53.46% |
| 10 | Ligand Pharmaceuticals | 5.89 Bn | 5.11 Bn | 48.45 Mn | -136.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -136.34% |
| Dec 31, 2025 | 253.08% |
| Sep 30, 2025 | 53.63% |
| Jun 30, 2025 | 162.99% |
| Mar 31, 2025 | -193.22% |
| Dec 31, 2024 | 230.62% |
| Sep 30, 2024 | 625.25% |
| Jun 30, 2024 | 46.99% |
| Mar 31, 2024 | -37.93% |
| Dec 31, 2023 | -92.43% |
| Sep 30, 2023 | -637.71% |
| Jun 30, 2023 | -520.64% |
| Mar 31, 2023 | 1,065.38% |
| Dec 31, 2022 | 1,146.58% |
| Sep 30, 2022 | -181.80% |
| Jun 30, 2022 | 4.68% |
| Mar 31, 2022 | 71.27% |
| Dec 31, 2021 | 99.05% |
| Sep 30, 2021 | -99.58% |
| Jun 30, 2021 | -328.15% |